A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
AI-Driven Decision Support Systems Reviewed for Heart Care Impact
A systematic review explores how AI-based clinical decision support systems can enhance cardiovascular disease management while facing adoption and equity challenges.
•EurekAlert
AI Transforms Early Detection and Prediction in Kidney Disease
Artificial intelligence is increasingly enabling earlier detection and improved prediction of kidney disease progression by leveraging complex clinical and imaging data.
•EurekAlert
Stanford Study: Physicians Plus AI Chatbots Improve Clinical Decision-Making
Stanford-led studies show that physicians supported by AI chatbots match or exceed chatbot-alone performance in nuanced clinical decision-making.